A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir

Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chengyuan, Tian, Lei, Liu, Yuzhi, Hui, Nan, Qiao, Guaiping, Li, Han, Shi, Zhenfeng, Tang, Yonghong, Zhang, Dezhu, Xie, Xiaolin, Zhao, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834743/
https://www.ncbi.nlm.nih.gov/pubmed/32563812
http://dx.doi.org/10.1016/j.ejmech.2020.112527
_version_ 1783642352388145152
author Liang, Chengyuan
Tian, Lei
Liu, Yuzhi
Hui, Nan
Qiao, Guaiping
Li, Han
Shi, Zhenfeng
Tang, Yonghong
Zhang, Dezhu
Xie, Xiaolin
Zhao, Xu
author_facet Liang, Chengyuan
Tian, Lei
Liu, Yuzhi
Hui, Nan
Qiao, Guaiping
Li, Han
Shi, Zhenfeng
Tang, Yonghong
Zhang, Dezhu
Xie, Xiaolin
Zhao, Xu
author_sort Liang, Chengyuan
collection PubMed
description Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.
format Online
Article
Text
id pubmed-7834743
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-78347432021-01-26 A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir Liang, Chengyuan Tian, Lei Liu, Yuzhi Hui, Nan Qiao, Guaiping Li, Han Shi, Zhenfeng Tang, Yonghong Zhang, Dezhu Xie, Xiaolin Zhao, Xu Eur J Med Chem Review Article Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed. Elsevier Masson SAS. 2020-09-01 2020-06-06 /pmc/articles/PMC7834743/ /pubmed/32563812 http://dx.doi.org/10.1016/j.ejmech.2020.112527 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Liang, Chengyuan
Tian, Lei
Liu, Yuzhi
Hui, Nan
Qiao, Guaiping
Li, Han
Shi, Zhenfeng
Tang, Yonghong
Zhang, Dezhu
Xie, Xiaolin
Zhao, Xu
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title_full A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title_fullStr A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title_full_unstemmed A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title_short A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir
title_sort promising antiviral candidate drug for the covid-19 pandemic: a mini-review of remdesivir
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834743/
https://www.ncbi.nlm.nih.gov/pubmed/32563812
http://dx.doi.org/10.1016/j.ejmech.2020.112527
work_keys_str_mv AT liangchengyuan apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT tianlei apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT liuyuzhi apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT huinan apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT qiaoguaiping apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT lihan apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT shizhenfeng apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT tangyonghong apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT zhangdezhu apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT xiexiaolin apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT zhaoxu apromisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT liangchengyuan promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT tianlei promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT liuyuzhi promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT huinan promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT qiaoguaiping promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT lihan promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT shizhenfeng promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT tangyonghong promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT zhangdezhu promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT xiexiaolin promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir
AT zhaoxu promisingantiviralcandidatedrugforthecovid19pandemicaminireviewofremdesivir

Ejemplares similares